Legal & Legislative


Abbott Laboratories

in
Abbott has sued two top Indian drugmakers, Ranbaxy Laboratories Ltd. and Sun Pharmaceuticals in the US market alleging patent infringement in the cases of two different cholestrol drugs.

Glenmark Pharmaceutical

in
Glenmark Pharmaceutical has scored in its patent tussle with Sanofi-Aventis and Abbott Laboratories after the New Jersey district court upheld the challenge by the Indian company for a hyper-tension drug.

AstraZeneca

in
AstraZeneca accused nine rivals of patent infringement over plans to market a generic version of the cholesterol-control drug Crestor.

AstraZeneca

in
A federal judge in Delaware has refused to dismiss a lawsuit accusing AstraZeneca of anticompetitive practices involving the heart drug Toprol-XL.

Sanofi-Aventis, Bristol-Myers Squibb Company, and Apotex

in
A district court has ruled that three drug makers accused of delaying entry of a generic version of the blockbuster blood-thinner Plavix did not commit an antitrust violation. Lawsuits brought by direct purchasers of the drug failed to prove antitrust violations by Sanofi-Aventis and Bristol-Myers Squibb Company, which market Plavix, and Apotex, which briefly sold a generic version of the drug.

Edwards Lifesciences Corporation

in
Edwards Lifesciences Corporation announced that a federal jury found that Edwards' U.S. Andersen transcatheter heart valve patent is valid and that Medtronic CoreValve LLC willfully infringes it.

AHP Billing Services, Inc.

in
Advantedge Healthcare Solutions, Inc. acquired AHP Billing Services, Inc. from Anodyne Health, Inc. on March 24, 2010.

Athenahealth, Inc.

in
The law firm of Izard Nobel LLP announced that a lawsuit seeking class action status has been filed in the United States District Court for the District of Massachusetts on behalf of purchasers of the securities of Athenahealth, Inc. between October 29, 2009 and February 25, 2010, inclusive.

Blue Cross and Blue Shield of Massachusetts, Inc.

in
The president and CEO of Blue Cross and Blue Shield of Massachusetts, Inc. has resigned. Cleve Killingsworth left the company on March 15. William Van Faasen will serve as interim CEO while the search for a permanent replacement is under way.

MDS Pharma Services

in
MDS Pharma Services reports unaudited earnings results for the first quarter ended January 31, 2010; Records impairment charges for the first quarter of 2010
1234next ›last »
Syndicate content